AdvaMed Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why Lifesaving Medtech Should Be Tariff-free: An Interview with AdvaMed’s CEO
April 30, 2025
AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential, lifesaving medtech products.
News / China / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners
April 25, 2025
WASHINGTON – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech.
Blog / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Why the Administration Should Be Flexible with Medtech Tariffs to Protect Patients and Innovation
April 25, 2025
Flexibility on tariffs is critical to maintaining medtech as the backbone of the U.S. health care system and an American economic success story.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain
Tariffs: Understanding the Nairobi Protocol and related Customs Procedures
Now On Demand
Learn how the Nairobi Protocol may support duty-free access for medical devices under new tariffs. Join us April 30, 2–3:30pm ET.
News / Diagnostics / Digital Health / Government & Legislative Affairs / Regulatory Affairs
AdvaMed Releases “AI Policy Roadmap” to Guide Congress and Federal Agencies
April 22, 2025
Washington, D.C.—AdvaMed, the Medtech Association, today released its “AI Policy Roadmap,” a detailed policy outline for Congress and the federal agencies with jurisdiction over medtech to consider in promoting the next era of artificial intelligence-enabled medical and digital health technologies to provide patients and clinicians transformative new tools to aid in diagnosis and treatment.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
Scott Whitaker Op-Ed: Tariffs Should Spare Vital U.S. MedTech Industry
April 17, 2025
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs
AdvaMed® Advancements: Q1 2025 Report
April 15, 2025
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
News / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs
Bipartisan Health Tech Investment Act Will Enhance Patient Access to AI-Enabled Medical Devices
April 10, 2025
WASHINGTON – AdvaMed, the Medtech Association, today commended Senators Mike Rounds (R-SD) and Martin Heinrich (D-NM) for introducing the Health Tech Investment Act (S. 1399). This landmark bipartisan legislation will establish a stable reimbursement pathway for medical devices authorized by the U.S. Food & Drug Administration (FDA) that rely on artificial intelligence (AI) and machine learning (ML), also known as Algorithm-Based Healthcare Services (ABHS).